Number of tests performed/missed, by HbA1c level, compared with those performed in the 12 months prior to the COVID-19 impact period (CIP); (A) ‘monitoring’, (B) ‘screening’ and (C) ‘diagnostic’
| (A) Monitoring tests | ||||||||||
| Period | Testing | Good Control | Suboptimal Control | Total | Test per month | |||||
| <30 mmol/mol | 30–41 mmol/mol | 42–47 mmol/mol | 48–58 mmol/mol | 59–75 mmol/mol | 76–86 mmol/mol | >86 mmol/mol | ||||
| Pre-CIP | Tests performed | 361 (0.1%) | 16 552 (4.3%) | 62 368 (16.1%) | 147 279 (38.0%) | 101 081 (26.1%) | 28 650 (7.4%) | 31 074 (8.0%) | 387 365 | 32 280 |
| CIP | Tests performed | 205 (0.2%) | 5612 (4.7%) | 19 200 (16.0%) | 44 841 (37.3%) | 30 448 (25.3%) | 8950 (7.4%) | 10 932 (9.1%) | 120 188 | 19 138 |
| Missed tests | 65 (0.1%) | 3635 (4.6%) | 15 235 (19.3%) | 31 632 (40.0%) | 17 724 (22.4%) | 5066 (6.4%) | 5774 (7.3%) | 79 131 | 12 600 | |
| (B) Screening tests | ||||||||||
| Period | Testing | Within range | Pre-diabetes | Diabetes | Total | Test per month | ||||
| <30 mmol/mol | 30–41 mmol/mol | 42–47 mmol/mol | 48–58 mmol/mol | 59–75 mmol/mol | 76–86 mmol/mol | >86 mmol/mol | ||||
| Pre-CIP | Tests performed | 11 462 (1.9%) | 458 774 (76.5%) | 129 682 (21.6%) | – | – | – | – | 599 918 | 49 993 |
| CIP | Tests performed | 5039 (2.5%) | 155 909 (77.1%) | 41 342 (20.4%) | – | – | – | – | 202 290 | 32 212 |
| Missed tests | 2690 (1.8%) | 119 986 (80.3%) | 26 779 (17.9%) | – | – | – | – | 149 455 | 23 799 | |
| (C) Diagnostic tests | ||||||||||
| Period | Testing | Within range | Pre-diabetes | Diabetes | Total | Test per month | ||||
| <30 mmol/mol | 30–41 mmol/mol | 42–47 mmol/mol | 48–58 mmol/mol | 59–75 mmol/mol | 76–86 mmol/mol | >86 mmol/mol | ||||
| Pre-CIP | Tests performed | 12 100 (3.3%) | 304 514 (82.6%) | 35 009 (9.5%) | 7952 (2.2%) | 4184 (1.1%) | 1556 (0.4%) | 3195 (0.9%) | 368 510 | 30 709 |
| CIP | Tests performed | 4137 (5.4%) | 61 174 (79.6%) | 6816 (8.9%) | 2094 (2.7%) | 1085 (1.4%) | 465 (0.6%) | 1105 (1.4%) | 76 876 | 12 241 |
| Missed tests | 4050 (2.9%) | 121 501 (86.0%) | 11 880 (8.4%) | 2035 (1.4%) | 909 (0.6%) | 297 (0.2%) | 613 (0.4%) | 141 285 | 22 498 | |
Pre-CIP period defined as 1 March 2019 to 29 February 2020; CIP period defined as 23 March 2020 to 30 September 2020.
HbA1c, glycated haemoglobin.